825620-41-5

Upstream product

• 99974-66-0 diethyl 3-hydroxycyclobutane-1,1-dicarboxylate 
• 98-59-9 p-toluenesulfonyl chloride 
• 54166-15-3 diethyl 3-(benzyloxy)cyclobutane-1,1-dicarboxylate 

Downstream Products

• 1400273-64-4 diethyl 3-(p-tolylsulfinyl)cyclobutane-1,1-dicarboxylate 
• 1400273-65-5 3,3-bis(hydroxymethyl)cyclobutyl p-tolylsulfoxide 
• 1400273-66-6 [3-(p-tolylsulfinyl)cyclobutane-1,1-diyl]bis(methylene) dimethanesulfonate 
• 1400273-67-7 3,3-dimethylcyclobutyl p-tolylsulfoxide 
• 1400273-68-8 1-chloro-3,3-dimethylcyclobutyl p-tolylsulfoxide 
• 1400273-63-3 diethyl 3-(p-tolylthio)cyclobutane-1,1-dicarboxylate 

Relevant academic research and scientific papers

Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems

We describe herein the synthesis of a series of carboplatin derivatives with different functional groups at position 3 of the cyclobutane ring. This pharmacomodulation approach aims at facilitating the vectorisation of these analogues, via their subsequen

Liver targeting of platinum-based anti-cancer medicine and its synthesis method

The invention discloses a liver-targeting platinum anticancer drug and a synthetic method thereof, and relates to the liver-targeting platinum anticancer drug which uses cholic acid and derivatives thereof as carrier molecules, and the synthetic method thereof. According to the invention, ammonia/amine ligand (A2) of the liver-targeting platinum anticancer drug comprises 2NH3, 1R,2R-diaminocyclohexane, 1,2-bis(aminomethyl)cyclobutane, (4S,5S)-4,5-(aminomethyl)-2-isopropyl-1,3-dioxolane, cholic acid, deoxycholic acid, hyodeoxycholic acid, ursodeoxycholic acid and chenodeoxycholic acid (RCOOH). The cholic acid and derivatives thereof are conjugated with 1,1-cyclobutane dicarboxylic radicals through amide bonds to form compounds with a structure as described in the specification. The compounds have the characteristics of high anticancer activity and strong liver-targeting property and can be applied as the anticancer drug to hepatic artery infusion or hepatic artery intervention embolization therapy for liver cancer; the structural formula of the compounds is described in the specification.

Synthesis of spiro[26]nonadienones and spiro[3.6]decadienones by the reaction of cyclopropyl- and cyclobutylmagnesium carbenoids with lithium phenolates and naphtholates

Treatment of 1-chlorocyclopropyl p-tolyl sulfoxides and 1-chlorocyclobutyl p-tolyl sulfoxides with a Grignard reagent at low temperature afforded cyclopropylmagnesium carbenoids and cyclobutylmagnesium carbenoids, respectively, via a sulfoxide-magnesium e